Biomerica Inc. BMRA
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
Biomerica Inc. (BMRA) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to August 31, 2026 it had revenue of $4M and net income of -$5M, a net margin of -115.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -9% a year, a 5-year average ROIC of -66%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.
About Biomerica
Biomerica is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $5M in 2015 to $4M in 2026, a decline of about 1.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 65% over three years (dilution for shareholders). It spends 18% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $4M | $5M | $5M | $5M | $19M | $7M | $7M | $5M | $6M | $6M |
| Net income | -$5M | -$4M | -$5M | -$6M | -$7M | -$5M | -$7M | -$3M | -$2M | -$1M | -$908561 |
| Free cash flow | — | — | — | -$5M | -$6M | -$536000 | -$5M | -$4M | -$2M | -$1M | -$818943 |
| EPS (diluted) | $-1.64 | $-1.30 | $-2.16 | $-2.84 | $-4.00 | $-2.88 | $-4.96 | $-2.08 | $-2.08 | $-1.36 | $-0.88 |
| Net margin | -115.5% | -84.8% | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -40.0% | -46.0% | -26.3% | -15.7% |
| ROIC | — | -93.1% | -88.9% | -68.2% | -44.6% | -36.9% | -54.6% | -13.5% | -47.9% | -27.1% | -16.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Biomerica stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biomerica pay a dividend?
Not currently.
Is Biomerica a good stock to buy?
We do not give buy or sell advice. Biomerica scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.